FDA Publishes Compounding Guidance on the Evaluation of Bulk Drug Substances
The draft guidance addresses the agency’s policy on evaluating bulk drug substances in drug compounding.
On March 23, 2018, FDA released draft guidance on drug compounding as part of its implementation of the Drug Quality and Security Act and section 503B of the Federal Food, Drug, and Cosmetic (FD&C) Act. The new draft guidance details the agency’s policy for evaluating bulk drug substances in compounding by outsourcing facilities registered under section 503B of the FD&C Act.
The guidance addresses the agency’s policies for developing bulk lists, including the definition of “bulk drug substances for which there is a clinical need.” Factors and processes used by the agency to evaluate bulk drug substances are also discussed.
“Today’s draft guidance is a significant milestone in our work to implement that compounding priorities plan … As the agency further refines what we intend our policies to be on this important topic, we know that stakeholders will, through the public comment process, bring competing concerns to our attention,” FDA Commissioner Scott Gottlieb, MD, stated in a press release.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
